Trials / Completed
CompletedNCT04711655
Antireflux Ablation of the Cardia Mucosa vs Placebo for the Treatment of Gastroesophageal Reflux Disease
Double-blind, Placebo-controlled Clinical Trial on the Efficacy of Antireflux Ablation of the Cardiac Mucosa for the Treatment of Gastroesophageal Reflux Disease
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The ARMA technique improves GORD-related quality of life with a low proportion of adverse effects.
Detailed description
Gastroesophageal reflux disease (GERD) is defined as the presence of symptoms or complications secondary to the passage of gastric contents into the esophagus, oral cavity or structures of the airway. The prevalence worldwide is between 8-33%. The clinical practice guidelines of the American College of Gastroenterology establish that first-line treatment, in the absence of alarm symptoms, should be carried out empirically. This treatment consists of hygienic-dietary measures and the use of proton pump inhibitors (PPIs) for 8-12 weeks. Despite the proven effectiveness of PPIs, there is 10-40% of patients who do not respond adequately to this treatment. All this has motivated the appearance of endoscopic and surgical techniques that offer an alternative to medical treatment. Among them is the technique of antireflux ablation of the cardiac mucosa (ARMA) in which the resection of the mucosa is replaced by an ablation with electrocoagulation current or by argon gas fulguration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | ARMA (antireflux ablation of the cardiac mucosa) | is an endoscopy in which argon gas ablation of the cardiac mucosa |
| PROCEDURE | upper digestive endoscopy | Quality diagnostic upper gastrointestinal endoscopy will be performed without intervention in patients assigned to this treatment arm. |
Timeline
- Start date
- 2021-03-01
- Primary completion
- 2023-12-31
- Completion
- 2025-02-07
- First posted
- 2021-01-15
- Last updated
- 2025-04-24
Locations
9 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT04711655. Inclusion in this directory is not an endorsement.